---
title: "Chemspec issued a profit warning, expecting a net loss of 46 million to 55 million yuan in 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225810798.md"
description: "According to the announcement from Chemspec, the company expects to incur a net loss attributable to the owners of the parent company for the fiscal year 2024, with a net loss ranging from 46 million yuan to 55 million yuan. Compared to the same period last year (statutory disclosure data), this represents a decrease of 158.6991 million yuan to 167.6991 million yuan, a year-on-year decrease of 140.82% to 148.80%"
datetime: "2025-01-22T09:26:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225810798.md)
  - [en](https://longbridge.com/en/news/225810798.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225810798.md)
generator: "portal-rs"
---

# Chemspec issued a profit warning, expecting a net loss of 46 million to 55 million yuan in 2024

According to the announcement from Chemspec (688602.SH), the company expects to report a net loss attributable to the owners of the parent company for the year 2024, with the net loss estimated to be between 46 million yuan and 55 million yuan. This represents a decrease of 158.6991 million yuan to 167.6991 million yuan compared to the same period last year (statutory disclosure data), reflecting a year-on-year decrease of 140.82% to 148.80%

### Related Stocks

- [688602.CN](https://longbridge.com/en/quote/688602.CN.md)

## Related News & Research

- [Indonesian tycoon Haji Isam bids for stake in miner Bayan, Bloomberg News reports](https://longbridge.com/en/news/298410137.md)
- [Promise Launches Clinician-Guided BPC-157 Evaluation as FDA Panel Backs 503A Bulks List Addition](https://longbridge.com/en/news/298349678.md)
- [EIQ: FDA setback delays heart failure solution, but strong finances and U.S. growth continue](https://longbridge.com/en/news/298376891.md)
- [DisposeRx Launches The Medication Stewardship Center to help redefine how each of us thinks about our own and our families' prescription journeys](https://longbridge.com/en/news/298490700.md)
- [FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia](https://longbridge.com/en/news/298434196.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**